🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

217 results for “Merck Sharp and Dohme” Clear

  1. -, -, PACLITAXEL , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-2870, MK-2870, DOXORUBICIN , CAPECITABINE , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE , PARACETAMOL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  2. -, DOCETAXEL , DEXAMETHASONE , -, -, MK-2870, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. -, IRINOTECAN , PARACETAMOL , -, -, PACLITAXEL , TRIFLURIDINE, COMBINATIONS, MK-2870, DOCETAXEL

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CAPECITABINE , PARACETAMOL , MK-2870, DEXAMETHASONE

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  5. -, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MK-2870, Avastin 25 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Merck Sharp and Dohme

    Ovarian cancer

    phase 3 small molecule active

    1 trial

  6. -, PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., MK-2870, MVASI 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., CISPLATIN

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 small molecule active

    1 trial

  7. -, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  8. ACALABRUTINIB , Nemtabrutinib, Nemtabrutinib, Nemtabrutinib, Nemtabrutinib, IBRUTINIB

    Merck Sharp and Dohme

    Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  9. ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A

    Merck Sharp and Dohme

    Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea

    phase 3 small molecule active

    1 trial

  10. Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  11. BEVACIZUMAB, PARACETAMOL , MK-2870, DEXAMETHASONE, BEVACIZUMAB , -, -, MK-2870, -

    Merck Sharp and Dohme

    Ovarian cancer recurrent

    phase 3 small molecule active

    1 trial

  12. Bavencio 20 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Solid Tumors

    phase 3 small molecule active

    1 trial

  13. Belzutifan, CABOZANTINIB , Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Advanced RCC with clear cell component

    phase 3 small molecule active

    1 trial

  14. CARBOPLATIN , -, -, PARACETAMOL , CIMETIDINE , DOCETAXEL , PACLITAXEL , MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    pMMR endometrial carcinoma

    phase 3 small molecule active

    1 trial

  15. CARBOPLATIN, PACLITAXEL, DOCETAXEL, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  16. CISPLATIN , PACLITAXEL , GEMCITABINE , CARBOPLATIN , placebo for mRNA-4157, PEMETREXED , mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. CYCLOPHOSPHAMIDE , -, PREDNISONE , PREDNISOLONE , VINCRISTINE, DOXORUBICIN , RITUXIMAB , Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  18. Cabozantinib Ipsen 60 mg film-coated tablets, XL092, XL092, XL092, BELZUTIFAN, Cabozantinib Ipsen 20 mg film-coated tablets, XL092

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  19. DEXAMETHASONE , MK-2870, -, -, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -

    Merck Sharp and Dohme

    Metastatic non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  20. DOCETAXEL , MK-2870, VINFLUNINE , PACLITAXEL , MK-2870, -, -

    Merck Sharp and Dohme

    Locally advanced/metastatic urothelial carcinoma

    phase 3 small molecule active

    1 trial

  21. DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  22. EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, Placebo to BIK/FTC/TAF, islatravir, ulonivirine, MK-8591B, Placebo to 8591B

    Merck Sharp and Dohme

    HIV

    phase 3 small molecule active

    1 trial

  23. FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  24. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Merck Sharp and Dohme

    ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.​

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources